This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Neogen (NEOG) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance in both its Animal Safety and Food Safety segments during the fiscal third quarter pushes Neogen (NEOG) to a 52-week high.
Here's Why You Should Hold NextGen (NXGN) in Your Portfolio
by Zacks Equity Research
Investor optimism is high on NextGen (NXGN) stock, courtesy of its solid prospects.
Merck KGaA Chooses PRA Health's (PRAH) Remote Monitoring Tool
by Zacks Equity Research
PRA Health's (PRAH) remote patient monitoring platform will enable Merck KGaA to offer patients an array of advanced tools to help manage their conditions.
PAHC or SRDX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PAHC vs. SRDX: Which Stock Is the Better Value Option?
BD's (BDX) $65M Investment to Boost Supply-Chain Strength
by Zacks Equity Research
BD's (BDX) $65-million investment in constructing an advanced facility will become integral to the U.S. medical device supply chain.
Here's Why You Should Retain Luminex (LMNX) Stock for Now
by Zacks Equity Research
Investor confidence is high in Luminex (LMNX) stock, courtesy of its solid prospects.
Buy 3 MedTech Stocks That Are Outperforming S&P 500 in 2021
by Sriparna Ghosal
Let's take a look at the three MedTech stocks performing well lately, banking on a host of impressive developments.
Here's Why You Should Hold on to Ecolab (ECL) Stock for Now
by Zacks Equity Research
Ecolab (ECL) continues to gain traction for a solid product portfolio and cost-efficiency program. However, segmental weakness is worrisome.
BD (BDX) Receives FDA EUA for Combination Rapid Antigen Test
by Zacks Equity Research
BD (BDX) gets FDA EUA for new rapid, antigen test, which can distinguish between COVID-19, influenza A and influenza B in a single test.
PerkinElmer's (PKI) Horizon Discovery Broadens Portfolio
by Zacks Equity Research
PerkinElmer's (PKI) CRISPRi will help scientists get a firmer foothold in the biological pathways, processes and pathologies of disease.
Why You Should Add Surmodics (SRDX) to Your Portfolio Now
by Zacks Equity Research
Investor optimism is high on Surmodics (SRDX) stock, courtesy of its solid prospects.
Surmodics (SRDX) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Surmodics (SRDX) records higher revenues in its In Vitro Diagnostics core unit in the fiscal first quarter.
SurModics (SRDX) Beats Q1 Earnings Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 133.33% and -3.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate SurModics (SRDX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PAHC vs. SRDX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PAHC vs. SRDX: Which Stock Is the Better Value Option?
Why Is SurModics (SRDX) Up 6.4% Since Last Earnings Report?
by Zacks Equity Research
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Surmodics (SRDX) Reports Q4 Loss, Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) registered revenue decline in each of its core units in the fourth quarter.
SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of -1900.00% and 4.03%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: SurModics (SRDX) Q4 Earnings Expected to Decline
by Zacks Equity Research
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: SurModics (SRDX) Q4 Earnings Expected to Decline
by Zacks Equity Research
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NUVA or SRDX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NUVA vs. SRDX: Which Stock Is the Better Value Option?
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
by Zacks Equity Research
Investor confidence is high on OPKO Health (OPK), thanks to solid prospects.
Thermo Fisher Rides on End Market Growth, Test Revenues
by Zacks Equity Research
Thermo Fisher's (TMO) pharma and biotech end markets register growth on robust performance in bioproduction and pharma services businesses.
Veeva Collaborates With RedHill for Coronavirus Clinical Study
by Zacks Equity Research
RedHill has adopted Veeva's (VEEV) Vault CDMS platform for the opaganib study.
Surmodics' Pounce Thrombus Retrieval System Gets FDA Nod
by Zacks Equity Research
The FDA clearance of Surmodics' (SRDX) Pounce Thrombus Retrieval System will bolster the current treatment of complex PAD.